GSK
GSK expands cost cutting drive
February 9, 2009Sales and Marketing GSK, restructure
GlaxoSmithKline has expanded its restructuring plans and will make widespread job cuts in a bid to cut costs throughout its …
GSK hopeful of NICE approval for Tyverb
January 26, 2009Sales and Marketing Cancer, GSK, breast cancer
NICE could be poised to reverse its rejection of GSK's breast cancer treatment Tyverb, the pharma company has said.NICE rejected …
GSK opens US hub for vaccine manufacturing
January 14, 2009Manufacturing and Production GSK
GlaxoSmithKline has officially unveiled a $300 million manufacturing plant in Pennsylvania that will serve as the cornerstone of its US …
GSK halts political funding
January 5, 2009Sales and Marketing GSK, ethics
GlaxoSmithKline will no longer make corporate political donations in a bid to make its dealings with governments more transparent and …
GSK to close Dartford manufacturing site by 2013
November 14, 2008Manufacturing and Production GSK
GlaxoSmithKline has announced plans to close its manufacturing site in Dartford in the UK, with operations being phased out over …
GSK delays US filing of Solzira
November 14, 2008Sales and Marketing GSK, restless legs
GlaxoSmithKline has withdrawn the US application for its restless legs syndrome treatment Solzira. The company, along with co-developer XenoPort, is …
GSK to acquire Hepatitis C specialists Genelabs
October 30, 2008Sales and Marketing GSK, Genelabs, MA
GlaxoSmithKline is to pay $57 million (£35 million) for Genelabs, California-based specialists in infectious diseases, including hepatitis C. The companies …
GSK takes Egyptian lead
October 16, 2008Sales and Marketing Egypt, GSK, em
GlaxoSmithKline has extended its reach into emerging markets by acquiring Bristol-Myers Squibb’s Egyptian mature products business for £125 millionThe move …
GSK’s pricing deal for Tyverb fails to sway NICE
October 15, 2008Sales and Marketing GSK, NICE, breast cancer
NICE has spurned GSK's risk-sharing proposal for its breast cancer treatment Tyverb, saying the drug is still too expensive to …
GSK plans research job losses in UK
October 3, 2008Research and Development GSK, restructure
GlaxoSmithKline is set to cut about 850 jobs in early-stage research and development at sites across the world, including the …
GSK seeks risk-sharing deal for Tyverb
September 17, 2008Sales and Marketing Cancer, GSK, NICE, par
GlaxoSmithKline has approached the government for a new pricing deal on its breast cancer drug Tyverb, which could make it …
GSK unveils new cancer unit
September 17, 2008Research and Development Cancer, GSK
GSK has unveiled a new integrated oncology R&D unit aimed at enhancing its presence in cancer care.The unit will be …
Viehbacher leaves GSK for Sanofi
September 10, 2008Sales and Marketing GSK, Sanofi
Chris Viehbacher is set to leave GlaxoSmithKline for a lead role at Sanofi-Aventis after last year losing out to Andrew …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
